Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00244543
Status:
COMPLETED
Last Update Posted:
2011-09-27
First Post:
2005-10-25
Brief Title:
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
Sponsor:
Vistakon Pharmaceuticals
Organization:
Vistakon Pharmaceuticals
Study Overview
Official Title:
A Single-Center Double-Masked Randomized Placebo-Controlled Evaluation of the Onset and Duration of Action of R89674 025 Ophthalmic Solution in Conjunctival Allergen Challenge CAC Model of Acute Allergic Conjunctivitis
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish the efficacy of R89674 025 ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None